DIOSynVax
DIOSynVax is a Cambridge-based biotechnology company revolutionizing vaccine antigen payload development to maximize vaccine protection worldwide against existing and future viruses. Their patented technology combines computational biology with in vitro and in vivo validation to design custom Vaccine Antigen Payloads (VAPs) that provide broad and deep immune protection, countering viral mutations and enabling proactive pandemic readiness. Their platform is vector-agnostic, allowing deployment across various vaccine platforms such as nucleic acid-based, virus vectored, or protein-based vaccines. DIOSynVax employs self-improving machine learning algorithms that continuously enhance vaccine design by analyzing virus structure and evolution. The company has demonstrated efficacy and safety in animal models for next-generation influenza vaccines, including a pandemic-ready universal bird flu vaccine, and is preparing for human trials. They collaborate internationally and have strategic partnerships supported by Innovate UK and Enterprise Singapore, positioning them as a leader in next-generation vaccine innovation and pandemic preparedness.
DIOSynVax
DIOSynVax is a Cambridge-based biotechnology company revolutionizing vaccine antigen payload development to maximize vaccine protection worldwide against existing and future viruses. Their patented technology combines computational biology with in vitro and in vivo validation to design custom Vaccine Antigen Payloads (VAPs) that provide broad and deep immune protection, countering viral mutations and enabling proactive pandemic readiness. Their platform is vector-agnostic, allowing deployment across various vaccine platforms such as nucleic acid-based, virus vectored, or protein-based vaccines. DIOSynVax employs self-improving machine learning algorithms that continuously enhance vaccine design by analyzing virus structure and evolution. The company has demonstrated efficacy and safety in animal models for next-generation influenza vaccines, including a pandemic-ready universal bird flu vaccine, and is preparing for human trials. They collaborate internationally and have strategic partnerships supported by Innovate UK and Enterprise Singapore, positioning them as a leader in next-generation vaccine innovation and pandemic preparedness.